Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006)
暂无分享,去创建一个
François Gouin | Bernard Regnier | Olivier Leroy | J. Carlet | B. Régnier | J. Mira | O. Lortholary | P. Montravers | Jean Carlet | J. Gangneux | Olivier Lortholary | Jean-Paul Mira | F. Gouin | J. Reynes | O. Leroy | M. Rosenheim | Philippe Montravers | Jean-Pierre Gangneux | Jean-Pierre Sollet | Jacques Reynes | Michel Rosenheim | J. Sollet
[1] Yee-Chun Chen,et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. , 2003, The Journal of antimicrobial chemotherapy.
[2] Victoria J. Fraser,et al. Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.
[3] H. Danawi,et al. Management of central venous catheters in patients with cancer and candidemia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] S. Fridkin,et al. Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 , 2005, Journal of Clinical Microbiology.
[5] B. Guidet,et al. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. , 2002, Journal of critical care.
[6] J. Sobel,et al. Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Kollef,et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia , 2007, Critical care medicine.
[8] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] T. Sorrell,et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections , 2004, Internal medicine journal.
[10] C. d’Enfert,et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome , 2008, Intensive Care Medicine.
[11] J. Serody,et al. Intravascular Catheter Exchange and Duration of Candidemia , 1995 .
[12] E. Johnson,et al. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990–9) , 2001, Epidemiology and Infection.
[13] A. Sitges-Serra,et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy , 1997, Intensive Care Medicine.
[14] M G Rinaldi,et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. , 1991, The New England journal of medicine.
[15] K. Laupland,et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.
[16] R. Wenzel,et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] M. Bassetti,et al. Epidemiological trends in nosocomial candidemia in intensive care , 2006, BMC infectious diseases.
[18] D. Pittet,et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] G. Jackson,et al. Gram-Negative Bacteremia: I. Etiology and Ecology , 1962 .
[20] J. D. De Waele,et al. Effect of fluconazole consumption on long-term trends in candidal ecology. , 2006, The Journal of antimicrobial chemotherapy.
[21] M. Cuenca‐Estrella,et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. , 2005, The Journal of antimicrobial chemotherapy.
[22] W. Hope,et al. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. , 2002, The Journal of hospital infection.
[23] P. Lipsett,et al. Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically Ill Surgical Patients , 2001, Annals of surgery.
[24] T. Peláez,et al. Mixed fungemia: incidence, risk factors, and mortality in a general hospital. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Sfar,et al. [Management of invasive candidiasis and aspergillosis in adults]. , 2004, Revue de pneumologie clinique.
[26] A. Tortorano,et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. , 2002, The Journal of hospital infection.
[27] J. Trupl,et al. Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] E. Anaissie,et al. The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[30] Shane Gillespie,et al. Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] D. Church,et al. Invasive Candida species infections: a 5 year population-based assessment. , 2005, The Journal of antimicrobial chemotherapy.
[32] S. Fridkin,et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[33] J. Vincent,et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care , 1998, Intensive Care Medicine.
[34] S. Lemeshow,et al. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. , 1993, JAMA.
[35] J. Serody,et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] E. Anaissie,et al. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.